2 4 24 38 39 40 42 43 45 87 90 1 B E I G E N E, L T D. 2 0 1 8
FCIS FCS Scott A. Samuels Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley Thomas Malley Ranjeev Krishana Donald W. Glazer Michael Goller The offices of Mourant Governance Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108 Cayman Islands 30 33 1 19 1901 B E I G E N E, L T D. 2 0 1 8 2
Mourant Ozannes Morgan Stanley & Co. Inc. 06160 www.beigene.com 29 20 183 17 1712-1716 Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 Cayman Islands 3 B E I G E N E, L T D. 2 0 1 8
BeiGene, Ltd. (1) zanubrutinib (BGB-3111) (BTK) (2) tislelizumab (BGB-A317) PD-1 (3) pamiparib (BGB-290) PARP1 PARP2 2 3 2018 zanubrutinib tislelizumab 2019 zanubrutinib 1 lifirafenib(bgb-283) RAF BGB-A333 PD-L1 BGB-A425 T 3(TIM-3) 2017 tislelizumab tislelizumab ABRAXANE REVLIMID VIDAZA 2017 9 2010 (Fort Lee) (Emeryville) (San Mateo) B E I G E N E, L T D. 2 0 1 8 4
2018 7 22 tislelizumab (chl) 70 chl Lugano(2014) 72.9% 50% tislelizumab 1 PD-1 chl chl BLA 2018 7 30 SEC 8-K 24 2018 7 22 18 2018 5 25 7.85 85.7% 61.4% 2018 7 22 zanubrutinib WM zanubrutinib WM 1 2019 1 zanubrutinib WM zanubrutinib WM 3 2018 7 24 pamiparib 3 2018 7 24 tislelizumab IIIB IV NSCLC 3 2018 7 27 65,600,000 2018 8 8 870,107,000 2018 8 8 5 B E I G E N E, L T D. 2 0 1 8
2017 9 tislelizumab 2017 pamiparib lifirafenib 2013 ABRAXANE REVLIMID VIDAZA 2018 2017 B E I G E N E, L T D. 2 0 1 8 6
zanubrutinib BTK tislelizumab PD-1 pamiparib PARP1 PARP2 lifirafenib BRAF BGB-A333 PD-L1 BGB-A425 TIM-3 7 B E I G E N E, L T D. 2 0 1 8
18A.08(3) B E I G E N E, L T D. 2 0 1 8 8
ABRAXANE REVLIMID VIDAZA 9 B E I G E N E, L T D. 2 0 1 8
2018 2017 6 30 6 6 30 6 2018 2017 % 54,676 54,676 30,672 30,672 85,348 85,348 (10,806) (10,806) (273,951) (90,018) (183,933) 204% (74,075) (19,546) (54,529) 279% (375) (375) (359,207) (109,564) (249,643) 228% (273,859) (109,564) (164,295) 150% 3,444 (1,796) 5,240-292% 804 438 366 84% (269,611) (110,922) (158,689) 143% 6,780 (381) 7,161-1880% (262,831) (111,303) (151,528) 136% (1,348) (135) (1,213) 899% BeiGene, Ltd. (261,483) (111,168) (150,315) 135% B E I G E N E, L T D. 2 0 1 8 10
2018 2017 6 30 6 2017 6 30 6 2018 6 30 6 85.3 2018 2017 6 30 6 6 30 6 2018 2017 % 54,676 54,676 25,730 25,730 4,942 4,942 85,348 85,348 2018 6 30 6 54.7 ABRAXANE REVLIMID VIDAZA 2017 9 VIDAZA 2018 2 2017 6 30 6 2018 6 30 6 30.6 25.7 3.4 (Merck KGaA, Darmstadt Germany) 1.5 2017 6 30 6 2017 6 30 6 2018 6 30 6 10.8 2018 6 30 6 2017 6 30 6 11 B E I G E N E, L T D. 2 0 1 8
2017 6 30 6 90.0 183.9 204% 2018 6 30 6 274.0 2018 2017 6 30 6 6 30 6 2018 2017 % 143,299 46,758 96,541 206% 28,331 5,341 22,990 430% 102,321 37,919 64,402 170% 273,951 90,018 183,933 204% zanubrutinib tislelizumab pamiparib 35.0 41.2 12.1 lifirafenib 1.8 sitravitinib 10 23.0 a) 26.0 b) 13.5 c) 9.9 d) 8.8 e) 6.2 B E I G E N E, L T D. 2 0 1 8 12
2017 6 30 6 19.5 54.5 279% 2018 6 30 6 74.1 20.1 9.5 4.7 20.2 2018 6 30 6 2017 6 30 6 1.8 3.4 2017 6 30 6 0.4 0.4 2018 6 30 6 0.8 2017 6 30 6 0.4 2018 6 30 6 6.8 2018 6 30 13 B E I G E N E, L T D. 2 0 1 8
2018 2017 6 30 6 262.8 111.3 2018 6 30 594.9 2018 2017 6 30 6 221.6 87.6 (Merck KGaA, Darmstadt Germany) 2018 6 30 6 757.6 2018 6 30 12.7 2018 2018 8 8 870,107,000 2018 8 8 2018 6 30 1,401.2 145.3 31.6 2018 2017 6 30 6 6 30 6 2018 2017 (221,638) (87,597) (360,220) 113,249 810,484 147,600 1,783 240 230,409 173,492 B E I G E N E, L T D. 2 0 1 8 14
2018 6 30 6 221.6 262.8 2.8 44.0 27.7 8.0 3.7 3.7 3.6 35.7 4.6 3.6 2018 6 30 6 36.0 Mirati 10.0 1.8 4.6 8.4 2017 6 30 6 87.6 111.3 12.6 11.1 2017 6 30 6 13.1 2.2 1.4 4.1 15 B E I G E N E, L T D. 2 0 1 8
2018 6 30 6 360.2 1,198.9 Mirati 10.0 20.3 869.0 2017 6 30 6 113.2 161.9 27.7 8.9 12.1 2018 6 30 6 810.5 757.6 42.3 10.6 2017 6 30 6 147.6 132.8 14.5 2017 B E I G E N E, L T D. 2 0 1 8 16
2018 6 30 12 zanubrutinib tislelizumab pamiparib 17 B E I G E N E, L T D. 2 0 1 8
2017 5 26 2018 6 30 1 1 3 3 5 5 38,275 11,982 18,903 6,658 732 209,751 9,067 9,140 151,698 39,846 55,957 55,957 303,983 77,006 28,043 158,356 40,578 B E I G E N E, L T D. 2 0 1 8 18
2015 9 2 7% 18.2 2018 6 30 18.2 19.6 2018 2019 9 30 9.1 2018 4 4 87.7 2019 12 31 12.1 2018 6 30 42.3 2021 2027 2017 3 7 900 8% 72 2017 4 14 2023 4 13 2017 4 14 900 2018 6 30 56.0 294 19 B E I G E N E, L T D. 2 0 1 8
2018 6 30 2017 12 31 438.4 239.6 31.6 931.2 597.9 2018 6 30 2018 6 30 B E I G E N E, L T D. 2 0 1 8 20
100 2018 6 30 2.8 2005 7 21 2018 6 30 6 2017 12 31 1.7% 6.5% 21 B E I G E N E, L T D. 2 0 1 8
1994 1 1 2018 6 30 6 2018 6 30 2018 6 30 2017 12 31 24.2% 17.1% 2018 6 30 2018 6 30 B E I G E N E, L T D. 2 0 1 8 22
2018 6 30 6 2018 6 30 1,250 2017 12 31 900 940 290 2018 6 30 6 107.4 2017 6 30 36.8 2018 6 30 31.6 2017 6 30 2018 6 30 19.6 2017 6 30 22.8 12.1 2017 6 30 2018 6 30 2017 6 30 2018 6 30 6 23 B E I G E N E, L T D. 2 0 1 8
2018 6 30 2018 6 30 XV 7 8 352 XV 352 (1) 34,110,070 (2) 4.44% 10,000,000 (3) 1.30% 102,188 (4) 0.01% 7,952,787 (5) 1.03% 29,872,444 (6) 3.89% 1,021,880 (7) 0.13% 16,214,750 (8) 2.11% 224,372 (9) 0.03% 5,000,000 (10) 0.65% 657,346 (11) 0.09% Donald W. Glazer 4,528,366 (12) 0.59% 38,160 (13) 0.00% Michael Goller 226,724 (14) 0.03% Ranjeev Krishana 226,724 (15) 0.03% Thomas Malley 1,139,472 (16) 0.15% 63,290 (17) 0.01% 226,724 (18) 0.03% B E I G E N E, L T D. 2 0 1 8 24
(1) 768,463,184 (2) (1) 16,270,707 (2) 16,689,898 (3) 1,149,465 (3) Roth IRA PENSCO (4) The John Oyler Legacy Trust (5) (6) Oyler Investment LLC Oyler Investment LLC 99% (7) The Oyler Family Legacy Trust (8) (1) 7,526,966 (2) 8,286,143 (3) 401,641 (9) (10) Wang Investment LLC Wang Investment LLC 99% (11) (1) 648,056 (2) 9,290 (12) (1)Glazer 4,301,642 (2) Glazer Glazer 217,434 (3)Glazer 9,290 (13) Glazer Glazer (14) (1) Goller Goller 217,434 (2)Goller 9,290 (15) (1) Krishana Krishana 217,434 (2)Krishana 9,290 (16) (1)Malley 390,000 (2) Malley Malley 740,182 (3)Malley 9,290 (17) 63,290 25 B E I G E N E, L T D. 2 0 1 8
(18) (1) 217,434 (2) 9,290 XV (a) XV (b) 352 (c) B E I G E N E, L T D. 2 0 1 8 26
2018 6 30 2018 6 30 XV 2 3 336 336 (1) Julian C. Baker (2) 161,880,677 21.07% Felix J. Baker (2) 161,880,677 21.07% Baker Bros. Advisors (GP) LLC. (2) 161,745,282 21.05% Baker Bros. Advisors LP (2) 161,745,282 21.05% Baker Brothers Life 145,425,622 18.92% Sciences Capital, L.P. (2) Hillhouse Capital 76,563,367 9.96% Management Ltd. (3) Gaoling Fund, L.P. (3) 58,995,800 7.68% Fidelity Management & 76,202,408 9.92% Research Company (4) FMR Co., Inc. (4) 71,180,714 9.26% FMR LLC (4) 77,169,208 10.04% Fidelity Mt. Vernon Street Trust (4) 38,393,094 5.00% Wellington Management 49,576,878 6.45% Group LLP (5) 27 B E I G E N E, L T D. 2 0 1 8
(1) 768,463,184 (2) Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC Baker Bros. Advisors (GP) LLC Baker Bros. Advisors LP. Baker Bros. Advisors LP. 667, L.P. Baker Brothers Life Sciences, L.P. Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC Baker Bros. Advisors L.P. 667, L.P. 16,319,660 Baker Brothers Life Sciences, L.P. 145,425,622 Julian C. Baker Felix J. Baker 92,326 FBB3 LLC 43,069 (3) (i)58,995,800 Gaoling Fund, L.P. (ii)4,121,589 YHG Investment, L.P. (iii)13,445,978 Hillhouse BGN Holdings Limited Hillhouse Capital Management, Ltd. YHG Investment, L.P. Gaoling Fund, L.P. Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited Hillhouse Capital Management, Ltd. Gaoling Fund, L.P. 58,995,800 YHG Investment, L.P. 4,121,589 Hillhouse BGN Holdings Limited 13,445,978 Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited 13,445,978 (4) Johnson Abigail P. Johnson FMR LLC B FMR LLC 49Johnson B B B Fidelity Management & Research Company 76,202,408 69,720,508 FMR Co., Inc 12,048,805 71,180,714 Fidelity Management & Research(Hong Kong) Limited 4,694,900 Fidelity Mt. Vernon Street Trust 38,393,094 Fidelity Mt. Vernon Street Trust 274,453 36,118,641 FMR Co., Inc. 71,180,714 FMR Co., Inc. 4,617,100 66,563,614 (5) Wellington Management Group LLP 38,453,845 Wellington Management Company LLP Wellington Management Singapore Pte Ltd Wellington Management Hong Kong Ltd Wellington Management International Ltd Wellington Wellington Investment Advisors Holdings LLP Wellington Management Global Holdings, Ltd. Wellington Wellington Investment Advisors Holdings LLP Wellington Group Holdings LLP Wellington Group Holdings LLP Wellington Management Group LLP Wellington Management Group (LLP) Wellington Investment Advisors Holdings LLP Wellington Management Global Holdings, Ltd. Wellington Group Holdings LLP Wellington 38,453,845 336 B E I G E N E, L T D. 2 0 1 8 28
1. 2011 2011 4 15 2015 4 17 2011 2018 6 30 2011 240 2011 2011 5 20 2016 1 31 2011 0.01 1.85 2011 20 2018 1 1 21,550,936 2011 2018 6 30 19,598,183 2011 2018 1 1 2018 6 30 2011 2018 2018 1 1 6 30 2011 5 20 10 2013 4 3 10 2015 6 29 10 Thomas Malley 2016 1 25 10 0.01 88,235 88,235 0.01 879,267 879,267 0.50 500,000 500,000 1.85 552,752 552,752 2015 6 29 0.50 4,900,000 455,000 4,445,000 10 2011 14,630,682 1,413,698 84,055 13,132,929 5 20 10 0.01 2016 1.85 1 31 21,550,936 1,868,698 84,055 19,598,183 29 B E I G E N E, L T D. 2 0 1 8
2. 2016 2016 2016 1 14 2011 2018 8 7 2016 2016 2016 2016 2 2 2018 6 30 2016 725 2016 2016 2 8 2018 6 26 2016 0.5 16.15 2016 20 2018 1 1 90,251,295 2016 2018 6 30 89,918,184 2016 2018 1 1 2018 6 30 B E I G E N E, L T D. 2 0 1 8 30
2016 2018 1 1 2018 6 30 2016 11 16 10 2017 9 27 10 2018 4 30 10 2018 6 26 10 2016 11 16 10 2017 9 27 10 2018 6 26 10 2016 2 8 10 2017 6 2 10 2018 6 6 10 Donald W. Glazer 2017 4 19 10 2018 6 6 10 Michael Goller 2017 4 19 10 2018 6 6 10 Ranjeev Krishana 2017 4 19 10 2018 6 6 10 Thomas Malley 2017 6 2 10 2018 6 6 10 2018 4 1 10 2017 4 19 10 2018 6 6 10 2.84 2,047,500 2,047,500 7.70 935,000 935,000 13.04 996,810 996,810 12.34 1,310,088 1,310,088 2.84 1,613,430 1,613,430 7.70 750,000 750,000 12.34 655,044 655,044 2.43 460,626 460,626 3.15 169,988 169,988 16.15 17,442 17,442 2.83 199,992 199,992 16.15 17,442 17,442 2.83 199,992 199,992 16.15 17,442 17,442 2.83 199,992 199,992 16.15 17,442 17,442 3.15 169,988 169,988 16.15 17,442 17,442 12.72 63,290 63,290 2.83 199,992 199,992 16.15 17,442 17,442 31 B E I G E N E, L T D. 2 0 1 8
2018 1 1 6 30 2016 11 16 10 2.84 1,752,500 1,752,500 2017 6 29 10 3.46 1,250,000 1,250,000 2018 6 26 10 12.34 364,208 364,208 Amy Peterson 2016 8 22 10 2.24 1,600,000 1,600,000 2017 6 27 10 3.49 1,016,178 1,016,178 2018 6 26 10 12.34 310,180 310,180 2016 9 2 10 2.27 1,367,500 1,367,500 2017 6 27 10 3.49 980,465 980,465 2018 6 26 10 12.34 310,180 310,180 2018 4 30 10 13.05 766,599 766,599 2016 2 8 2018 6 26 10 0.50 13.55 75,338,152 3,584,835 4,075,046 4,723,951 70,123,990 90,251,295 8,465,886 4,075,046 4,723,951 89,918,184 3. 2018 2018 6 6 2018 2018 8 7 2018 85% 2018 6 30 B E I G E N E, L T D. 2 0 1 8 32
4. 2018 2018 6 6 2018 12,000,000 2018 2018 8 7 2018 2018 2016 2018 2018 6 30 2010 10 28 2018 6 30 A.2.1 A.5.6 33 B E I G E N E, L T D. 2 0 1 8
3.21 C.3.3 C.3.7 SEC Thomas Malley Thomas Malley 3.10 (2) 3.21 3.25 B.1.2 Ranjeev Krishana A.5.2 Donald W. Glazer Michael Goller Donald W. Glazer 2018 6 30 B E I G E N E, L T D. 2 0 1 8 34
B.8 Scott A. Samuels Scott A. Samuels 13.51B(1) 13.51B(1) 2018 8 8 870,107,000 2018 6 30 27 35 B E I G E N E, L T D. 2 0 1 8
2018 2017 6 30 2018 2017 6 30 3000 3000 (i) (ii) 27 27 2018 2017 6 30 2018 6 30 2017 12 31 27 (iii) 27 3000 (i) 27 (ii) 27 (iii) 27 B E I G E N E, L T D. 2 0 1 8 36
Thomas Malley Thomas Malley 2018 6 30 13.20 13.21 13.22 2018 8 30 37 B E I G E N E, L T D. 2 0 1 8
6 30 2018 2017 17 54,676 3 30,672 85,348 (10,806) (273,951) (90,018) (74,075) (19,546) (375) (359,207) (109,564) (273,859) (109,564) 3,444 (1,796) 804 438 18 (269,611) (110,922) 12 6,780 (381) (262,831) (111,303) (1,348) (135) BeiGene, Ltd. (261,483) (111,168) BeiGene, Ltd. 19 (0.38) (0.22) 19 684,586,086 517,054,109 (4.97) (2.80) 52,660,468 39,773,393 B E I G E N E, L T D. 2 0 1 8 38
6 30 2018 2017 (262,831) (111,303) 2,305 644 1,048 7 (259,478) (110,652) (1,326) (108) BeiGene, Ltd. (258,152) (110,544) 39 B E I G E N E, L T D. 2 0 1 8
2018 6 30 2017 12 31 438,420 239,602 5 31,591 5 931,208 597,914 6 33,171 29,428 6 12,702 7 6,322 10,930 14 63,293 35,623 1,516,707 913,497 8 90,510 62,568 10 12,132 12,465 11 6,875 7,250 4 109 109 12 16,071 7,675 14 11,452 42,915 137,149 132,982 1,653,856 1,046,479 13 85,878 69,779 14 75,037 49,598 15,302 12,233 12 1,151 9,156 15 9,067 9,222 186,435 149,988 B E I G E N E, L T D. 2 0 1 8 40
2018 6 30 2017 12 31 15 51,467 9,222 16 149,217 146,271 18,297 24,808 14 21,772 31,959 240,753 212,260 427,188 362,248 24 0.0001 9,500,000,000 2018 6 30 701,563,184 2017 12 31 592,072,330 70 59 1,804,942 1,000,747 3,114 (480) (594,929) (330,517) BeiGene, Ltd. 1,213,197 669,809 21 13,471 14,422 1,226,668 684,231 1,653,856 1,046,479 41 B E I G E N E, L T D. 2 0 1 8
2017 12 31 592,072,330 59 1,000,747 (480) (330,517) 669,809 14,422 684,231 1 263 (2,929) (2,666) 375 (2,291) 2018 1 1 592,072,330 59 1,000,747 (217) (333,446) 667,143 14,797 681,940 102,970,400 10 757,577 757,587 757,587 727,927 36,037 36,037 36,037 5,792,527 1 10,581 10,582 10,582 (261,483) (261,483) (1,348) (262,831) 3,331 3,331 22 3,353 2018 6 30 701,563,184 70 1,804,942 3,114 (594,929) 1,213,197 13,471 1,226,668 2016 12 31 515,833,609 52 591,213 (946) (237,412) 352,907 352,907 492,471 14,527 14,527 13,074 13,074 13,074 2,576,269 316 316 316 (111,168) (111,168) (135) (111,303) 624 624 27 651 2017 6 30 518,902,349 52 604,603 (322) (348,580) 255,753 14,419 270,172 B E I G E N E, L T D. 2 0 1 8 42
6 30 2018 2017 (262,831) (111,303) 4,580 1,404 20 36,037 13,074 1 10,000 4,115 2,232 (8,413) (4,059) (2,336) (3) (3,743) 3,605 4,608 (27,669) (5,036) (3,694) (139) 10,308 13,242 25,439 130 (8,005) 2,302 (3,442) (197) 559 (221,638) (87,597) (20,309) (8,881) (12,124) (1,198,922) (27,646) 869,011 161,900 1 (10,000) (360,220) 113,249 43 B E I G E N E, L T D. 2 0 1 8
6 30 2018 2017 758,001 (414) 15 42,315 2,470 (2,470) 14,527 16 132,757 10,582 316 810,484 147,600 1,783 240 230,409 173,492 239,602 87,514 470,011 261,006 438,420 261,006 31,591 11,842 746 667 618 8,006 1,373 2,291 B E I G E N E, L T D. 2 0 1 8 44
1. 2017 9 2010 10 2016 2 Celgene Switzerland LLCCelgene Switzerland 22 2018 8 8 870,107,000 2018 8 8 2018 6 30 BeiGene (Hong Kong) 2010 11 22 100% Co., Limited 2011 1 24 100% BeiGene AUS PTY LTD. 2013 7 15 100% BeiGene 101 2012 8 30 100% 2015 4 9 100% BeiGene USA, Inc. 2015 7 8 100% 2017 1 25 95% * 2015 9 11 95% 45 B E I G E N E, L T D. 2 0 1 8
1. 2017 3 3 95% * 2017 7 11 100% 2009 12 15 100% BeiGene Switzerland GmbH 2017 9 1 100% BeiGene Ireland Limited 2017 8 11 100% * 2018 6 30 2018 2017 6 30 2018 2017 6 30 2018 2017 6 30 B E I G E N E, L T D. 2 0 1 8 46
1. 2018 2 27 2017 12 31 10-K 2018 6 30 47 B E I G E N E, L T D. 2 0 1 8
1. 2014 5 2014-09 606 2014-09 2015-14 606 2014-09 2016-08 606 2014-09 2016-10 606 2014-09 2016-12 606 2014-09 2017-13 605 606 840 842 2017 7 20 EITF SEC 2017-14 220 605 606 33-10403 ASC 606-10-S25-1 2017 12 15 2016 12 15 2018 1 1 B E I G E N E, L T D. 2 0 1 8 48
1. (i) (ii) (iii) (iv) (v) 605 2017 12 31 2017 12 31 2018 3 2014-09 2018 1 1 16,307,000 49 B E I G E N E, L T D. 2 0 1 8
1. 2016 10 2016-16 740 2018 2016-16 2017 BeiGene (Hong Kong) Co., Limited 28,588,000 2017 12 31 2017 9,990,000 2017 12 31 2016 11 2016-18 2018 1 1 31,591,000 2017 1 2017-01 2018 1 1 2017 1 1 100% 4 B E I G E N E, L T D. 2 0 1 8 50
1. 2017 1 2017-04 2 2019 12 15 2017 1 1 2017 5 2017-09 (1) (2) 718 2018 1 1 2016-16 2018 1 1 2017 12 31 2016-16 2018 1 1 16,307 16,307 42,915 (28,588) 14,327 31,959 (9,990) 21,969 (480) 263 (217) (330,517) 16,307 (19,236) (333,446) 14,422 375 14,797 51 B E I G E N E, L T D. 2 0 1 8
1. 2016 2 2016-02 12 2018 12 15 2018 6 30 38,275,000 2016-02 2016-02 2016-02 2018 2 2018-02 220 2017 12 22 2018 12 15 2018 6 2018-07 718 718 718 2018 12 15 606 B E I G E N E, L T D. 2 0 1 8 52
1. 2017 12 31 2018 2016-16 2018 6 30 53 B E I G E N E, L T D. 2 0 1 8
2. 1 2 1 3 2018 6 30 2017 12 31 2018 6 30 1 2 3 5 903,415 17,621 10,172 9,988 127,423 1,068,619 B E I G E N E, L T D. 2 0 1 8 54
2. 2017 12 31 1 2 3 5 561,327 17,663 18,924 44,730 642,644 2018 6 30 2017 12 31 3. Celgene Switzerland 2017 7 5 Celgene Switzerland PD-1 tislelizumab (BGB-A317) PD-1 2017 8 31 Celgene Switzerland PD-1 A&R PD-1 55 B E I G E N E, L T D. 2 0 1 8
3. Celgene Switzerland A R PD-1 263,000,000 92,050,000 2017 170,950,000 2017 12 Celgene Switzerland 12 13,000,000 Celgene Holdings East Corporation A&R PD-1 tislelizumab A&R PD-1 tislelizumab tislelizumab tislelizumab 2018 2017 6 30 6 30 2018 2017 25,730 4,942 30,672 B E I G E N E, L T D. 2 0 1 8 56
3. Celgene Switzerland 2018 6 30 30,672,000 2018 6 30 25,730,000 16,307,000 2018 6 30 3,442,000 2018 5 pamiparib 3 1,500,000 2018 6 30 2017 6 30 4. 2017 8 31 28,138,000 Celgene Holdings East Corporation Celgene Switzerland 2017 7 5 4,532,000 23,606,000 22 109,000 7,500,000 20,529,000 57 B E I G E N E, L T D. 2 0 1 8
5. 2018 6 30 31,591,000 15 2018 6 30 902,771 644 903,415 17,612 9 17,621 10,172 10,172 930,555 653 931,208 2017 12 31 561,733 406 561,327 17,651 12 17,663 18,924 18,924 598,308 12 406 597,914 2018 6 30 1 2018 6 30 B E I G E N E, L T D. 2 0 1 8 58
6. 2018 6 30 2017 12 31 33,171 29,428 33,171 29,428 2018 6 30 2017 12 31 3 33,171 18,907 3 6 10,521 33,171 29,428 2018 6 30 2017 12 31 2018 6 30 2018 6 30 2017 12 31 3 12,702 59 B E I G E N E, L T D. 2 0 1 8
7. 2018 6 30 2017 12 31 6,322,000 10,930,000 8. 2018 6 30 2017 12 31 17,986 15,596 16,272 15,298 15,534 15,737 1,718 1,597 1,260 1,244 1,238 598 53,738 26,125 107,746 76,195 (17,236) (13,627) 90,510 62,568 2018 6 30 2017 12 31 53,738,000 26,125,000 2018 6 30 1,633,000 2018 2017 6 30 34,174,000 8,348,000 2018 2017 6 30 2018 2017 6 30 4,083,000 1,404,000 B E I G E N E, L T D. 2 0 1 8 60
9. 2017 3 7 200,000,000 95% 100,000,000 5% 16 900,000,000 2017 4 11 2017 4 13 2017 5 4 137,830,000 2,415,000 2020 4 10 2017 4 14 100,000,000 2017 4 14 900,000,000 16 2017 100% 100% 95% 2018 4 4 87,652,000 580,000,000 2018 6 30 42,315,000 15 2018 6 30 95% 5% 2018 6 30 145,279,000 61 B E I G E N E, L T D. 2 0 1 8
10. 2017 50 2018 6 30 2017 12 31 2018 6 30 2017 12 31 12,422 12,633 (290) (168) 12,132 12,465 2018 2017 6 30 122,000 2018 6 30 2018 124,000 2019 248,000 2020 248,000 2021 248,000 2022 248,000 2023 11,016,000 B E I G E N E, L T D. 2 0 1 8 62
11. 2018 6 30 2017 12 31 2018 6 30 2017 12 31 7,500 (625) 6,875 7,500 (250) 7,250 7,500 (625) 6,875 7,500 (250) 7,250 ABRAXANE REVLIMID VIDAZA CC-122 10 2018 2017 6 30 375,000 2018 6 30 2018 375,000 2019 750,000 2020 750,000 2021 750,000 2022 750,000 2023 3,500,000 63 B E I G E N E, L T D. 2 0 1 8
12. 2018 2017 6 30 6,780,000 (381,000) 2018 6 30 2017 6 30 2018 6 30 2018 6 30 2018 6 30 1,552,000 12 2018 6 30 634,000 2018 6 30 2017 12 31 2018 6 30 2012 2018 2015 2018 2010 2018 B E I G E N E, L T D. 2 0 1 8 64
13. 2018 2017 6 30 12 31 1 78,106 65,626 1 3 5,364 3,170 3 6 1,664 725 6 1 657 189 1 87 69 85,878 69,779 30 14. 2018 2017 6 30 12 31 41,723 21,156 14,469 9,894 1,791 1,557 5,310 3,016 63,293 35,623 65 B E I G E N E, L T D. 2 0 1 8
14. 2018 2017 6 30 12 31 6,306 12,867 28,588 5,146 1,460 11,452 42,915 2018 2017 6 30 12 31 18,201 17,051 41,601 18,721 687 3,997 14,548 9,829 75,037 49,598 2018 2017 6 30 12 31 21,449 31,804 323 155 21,772 31,959 B E I G E N E, L T D. 2 0 1 8 66
15. 2015 9 2 7% 18,134,000 2018 6 30 18,134,000 19,585,000 9,067,000 2018 9 30 9,067,000 2019 9 30 2018 4 4 87,652,000 580,000,000 2019 12 31 12,132,000 2018 6 30 42,315,000 2018 6 30 4.9% 2021 2027 2018 6 30 45,337,000 2018 6 30 752,000 2018 2017 6 30 12 31 9,067 9,222 9,067 9,222 2,554 39,846 60,534 18,444 67 B E I G E N E, L T D. 2 0 1 8
16. 2017 3 7 900,000,000 2017 4 14 900,000,000 8% 72 2017 4 14 2023 4 13 900,000,000 8% 835-20 2018 6 30 5,609,000 1,568,000 B E I G E N E, L T D. 2 0 1 8 68
17. ABRAXANE REVLIMID VIDAZA 2018 2017 6 30 6 30 2018 2017 55,155 (479) 54,676 2018 6 30 2017 12 31 3,997 479 (3,789) 2018 6 30 687 69 B E I G E N E, L T D. 2 0 1 8
18. 6 30 2018 2017 10,806 4,580 1,404 273,951 90,018 3,870 1,421 122 66,406 22,103 36,037 13,074 4,947 1,630 107,390 36,807 327 10 (3,228) 13 8,226 1,054 2 7 2017 2018 6 30 28,051,000 67,545,000 B E I G E N E, L T D. 2 0 1 8 70
19. 6 30 2018 2017 BeiGene, Ltd. (261,483) (111,168) 684,586,086 517,054,109 BeiGene, Ltd. (0.38) (0.22) 2018 2017 6 30 20. 2016 2016 1 14 2016 2016 2016 2 2 65,029,595 2016 2011 2011 2016 2011 2018 6 30 2011 2016 4,977,646 2016 2018 6 30 2016 8,465,886 1/13 9,254,232 2018 6 30 2016 89,918,184 10,526,672 71 B E I G E N E, L T D. 2 0 1 8
20. 2018 2018 6 6 2018 2018 12,000,000 5635(c)(4) 5635(c)(4) 2018 2018 2016 2018 6 30 2018 527,904 2018 6 30 2018 527,904 2018 2018 6 6 2018 3,500,000 2018 6 30 2018 2017 6 30 6 30 2018 2017 22,774 9,278 13,263 3,796 36,037 13,074 B E I G E N E, L T D. 2 0 1 8 72
21. 2018 6 30 13,471,000 2018 6 30 2018 6 30 5% 1,348,000 2018 6 30 2017 12 31 14,422 375 2018 1 1 14,797 (1,348) 22 22 2018 6 30 13,471 73 B E I G E N E, L T D. 2 0 1 8
22. 2018 1 22 S-3 101.00 7.77 7,425,750 96,534,750 495,050 6,435,650 757,587,000 A&R PD-1 2017 8 31 150,000,000 4.58 59.55 Celgene Switzerland 32,746,416 72,000 4(a)(2) D 23. 2018 6 30 2017 12 31 37,640,000 29,920,000 B E I G E N E, L T D. 2 0 1 8 74
24. 2018 2017 6 30 3,870,000 1,421,000 2018 6 30 2018 12 31 6 6,103 2019 12 31 11,064 2020 12 31 9,907 2021 12 31 5,784 2022 12 31 3,961 2023 12 31 1,456 38,275 2018 6 30 55,957,000 75 B E I G E N E, L T D. 2 0 1 8
25. (a) 2018 2017 6 30 6 30 2018 2017 50 50 (b) 6 30 2018 2017 2,090 1,594 40 18 11,206 4,860 13,336 6,472 26. 6 30 2018 2017 56,176 18,962 10,210 85,348 B E I G E N E, L T D. 2 0 1 8 76
27. 2018 6 30 (i)) (ii)) (iii)) (273,951) (14,228) (288,179) (74,075) (8,644) (82,719) (269,611) (22,872) (292,483) 6,780 (6,810) (30) (262,831) (22,872) (6,810) (292,513) BeiGene, Ltd. (261,483) (22,872) (6,810) (291,165) 77 B E I G E N E, L T D. 2 0 1 8
27. 2017 6 30 (i)) (ii)) (iii)) (90,018) (9,726) (99,744) (19,546) (2,244) (21,790) (110,922) (11,970) (122,892) (381) 2,453 2,072 (111,303) (9,517) (120,820) BeiGene, Ltd. (111,168) (9,517) (120,685) B E I G E N E, L T D. 2 0 1 8 78
27. 2018 6 30 (i)) (ii)) (iii)) 16,071 5,184* 8,617* 27,197 (2,675) 1,653,856 5,184* 5,942 1,664,982 1,804,942 22,872 307,894* (2,675) 2,196,573 46,047* 6,810 10,683* (594,929) (22,872) (307,894)* (6,810) (975,396) (40,825)* (2,066)* 13,471 (38)* 13,433 1,226,668 5,184 5,942 1,237,794 * 2017 12 31 79 B E I G E N E, L T D. 2 0 1 8
27. 2017 12 31 (i)) (ii)) (iii)) (iv)) (v)) 42,915 (26,090) (2,498) 14,327 7,675 5,184 8,617 21,476 1,046,479 5,184 8,617 (26,090) (2,498) 1,031,692 31,959 (9,990) 21,969 362,248 (9,990) 352,258 1,000,747 46,047 307,894* 10,683 1,365,371 (480) 263 (217) (330,517) (40,825) (307,894)* (2,066) (26,090) 6,854 (700,538) 14,422 (38) 375 14,759 684,231 5,184 8,617 (26,090) 7,492 679,434 * 2016 12 31 B E I G E N E, L T D. 2 0 1 8 80
27. (i) 2018 6 30 14,228,000 8,644,000 2017 6 30 9,726,000 2,244,000 2018 6 30 2017 6 30 2,453,000 2017 12 31 46,047,000 2017 12 31 5,184,000 38,000 2017 12 31 40,825,000 2017 12 31 2018 1 1 (ii) 81 B E I G E N E, L T D. 2 0 1 8
27. (ii) 2016 2 307,894,000 307,894,000 (iii) 2016-09 2017 12 31 8,617,000 2018 6 30 2017 12 31 2,675,000 2017 12 31 2,066,000 2017 12 31 2018 6 30 6,810,000 2017 6 30 2017 12 31 8,617,000 2,066,000 10,683,000 2018 1 1 B E I G E N E, L T D. 2 0 1 8 82
27. (iv) 740 2016-16 2017 100% 26,090,000 2017 12 31 2017 12 31 2017 6 30 2017 2018 1 1 2016-16 2017 26,090,000 2018 1 1 2018 1 1 (v) 9,990,000 2017 12 31 2017 12 31 2017 740 2,498,000 2017 12 31 2017 2017 12 31 375,000 263,000 83 B E I G E N E, L T D. 2 0 1 8
27. (v) 2017 6 30 2017 (iv) 2018 1 1 9,990,000 2,498,000 2018 1 1 375,000 263,000 2018 1 1 2018 1 1 28. 2017 12 31 2018 2 27 2017 10-K 2017 12 31 2017 12 31 B E I G E N E, L T D. 2 0 1 8 84
28. 2017 12 31 2017 12 31 2017 12 31 (i) (ii) (iii) 16,307 16,307 42,915 (26,090) (2,498) 14,327 1,046,479 16,307 (26,090) (2,498) 1,034,198 31,959 (9,990) 21,969 362,248 (9,990) 352,258 (480) 263 (217) (330,517) 16,307 (26,090) 6,854 (333,446) 14,422 375 14,797 684,231 16,307 (26,090) 7,492 681,940 (i) 606 2017 12 31 16,307,000 606 85 B E I G E N E, L T D. 2 0 1 8
28. (ii) 2016-16 100% 26,090,000 2017 12 31 2016-16 740 2017 12 31 (iii) 2016-16 2017 9,990,000 2017 12 31 2017 740 2,498,000 375,000 263,000 2017 6 30 2017 29. 2018 6 30 2017 6 30 30. 2018 8 30 B E I G E N E, L T D. 2 0 1 8 86
2011 2011 4 15 2015 4 17 2011 2016 2016 1 14 2018 8 7 2016 2018 2018 6 6 2018 8 7 2018 13 2017 1 25 95% 5% 2017 3 3 2015 4 9 1986 4 7 87 B E I G E N E, L T D. 2 0 1 8
BeiGene, Ltd. 2010 10 28 622 zanubrutinib (BGB-3111) tislelizumab (BGB-A317) PD-1 pamiparib (BGB-290) PARP1 PARP2 2011 2016 2018 1998 11 27 B E I G E N E, L T D. 2 0 1 8 88
2018 8 8 GEM 2018 7 30 2018 6 30 571 15 % 89 B E I G E N E, L T D. 2 0 1 8
BRAF B-raf BTK BTK BCR NSCLC PARP ADP DNA DNA PD-1 1 T pro-b PD-L1 PD-L2 PD-1 T RAF RAF BRAF-BRAF BRAF-CRAF CRAF-CRAF T T T B TIM-3 T 3 Th1 WM B E I G E N E, L T D. 2 0 1 8 90